Objective-To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the risk of breast cancer in women.
Introduction
The injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) has been used by over 10 million women but has still not been approved for marketing in several countries including the United States.' This is partly because it caused malignant mammary tumours in beagles." The relevance of this finding was debated,' and there have been few studies of the drug's relevance to breast cancer in women.` 4 The drug was introduced in New Zealand in 1969 and has been used more extensively there than in any other developed country. We conducted a national casecontrol study to find out if there was an association between it and breast cancer.
Subjects were selected from the population of women whose names were in a current electoral roll and whose telephone number could be found.
Subjects and methods
Details of methods in the first two vears of the studv have been described elsewhere. The National Cancer Registry (or, in the Auckland region, the Auckland Breast Cancer Study Group) identified 1452 women aged in whom breast cancer had been confirmed histologically between 1 July 1983 and 30 June 1987.
We excluded women who had had breast cancer diagnosed previously, those whose names were not in a current electoral roll, and those whose telephone number could not be found. After these exclusions 1126 patients remained. We required that they be interviewed between four and eight months after diagnosis (this was extended in the third and fourth years to 12 months after diagnosis.) This resulted in the exclusion of some of the women: table I gives the reasons why 225 potentially eligible patients were not interviewed. Forty three patients refused to be interviewed. Interviews were completed with 901 (950o) of the 944 women approached. After interview 10 were excluded because they had had breast cancer diagnosed previously or because their final diagnosis was not breast cancer.
Control women were selected randomly from the electoral rolls, and women whose telephone numbers could not be found were excluded. As age was not specified in the rolls we had to choose more women than were required. We began with the interviewer blind to whether the subject was a patient or a control; although patients reported their illness during the interview, this usually occurred after the contraceptive history had been taken. The proportions of patients and controls who had used medroxyprogesterone were 12 3% (110/891) and 13 5% (252/1864), respectively. Overall, the relative risk for those who had used it (adjusted for potentially confounding variables by logistic regression) was 1-0 (95% confidence interval 0 80 to 1 3). Table III gives the relative risk of breast cancer according to age at diagnosis or reference date and duration of use of medroxyprogesterone; risks were calculated relative to women in the same age group who had never used the drug. Overall, there was no increase in risk with duration of use. In women aged 25-34, however, the relative risk for those who had used it was 2 0 (1 0 to 3 8) and the highest risk was in women who had received it for six years or longer (relative risk 3 7; 0 63 to 21 5). The trend in risk with duration of use was significant in this age group (p<0001), although the significance depended on the difference between those who had used the drug and those who had not. Table IV gives the relative risks of breast cancer according to the age at which the women first used medroxyprogesterone. In women who had first used it before age 25 the relative risk was 1 5 (0 85 to 2-6). Again the highest risk was in women in this group who had used it for six years or longer: their risk was raised significantly (relative risk 4 2; 1 1 to 16 2). The trend in risk with duration of use was marginally significant in this group (p=0 06). In women who had first used the drug when they were older than 25 there was no increased risk of breast cancer. In an attempt to disentangle the effects of age at first use of medroxyprogesterone and age at diagnosis we estimated relative risks stratified according to both of these variables. The distributions of patients and controls did not identify either of these variables as the key factor. Medroxyprogesterone is a potent progestogen, which is delivered to the body in relatively high conDiscussion centrations,'°E ndogenous progesterone was formerly Our results show that there was no overall associa-thought to exert a protective effect by opposing tion between use of medroxyprogesterone and risk of oestrogen in the induction of breast cancer." This breast cancer. Increased relative risks were seen, hypothesis is not consistent with epidemiological however, in women who had used the drug and were evidence,'2 and Pike and Ross suggested that raised diagnosed as having breast cancer before age 35; in progesterone concentrations may increase the risk of those who used it for at least two years before age 25; breast cancer."3 Medroxyprogesterone at low and high and in those who had used it recently. The numbers of doses causes mammary carcinomas in beagles,' 2 but -women who had used the drug for long periods were the relevance of this finding has been disputed."4" A small, but the highest relative risks in young women public board of inquiry in the United States, however, and in women who had used it before age 25 were in reviewed the arguments for dismissing the beagle those who had used it long term. The estimates of model and concluded that none had been substantiated relative risk were adjusted for potential confounding adequately.2 factors; adjustment for use of oral contraceptives did Epidemiological data on the association between not affect the results.
medroxyprogesterone and breast cancer in women are
Although chance seems an unlikely explanation for sparse and conflicting. Early studies, including two these findings, possible sources of bias must be con-from Atlanta,'6 7 were difficult to interpret because of sidered. Selection bias should have been minimised by methodological limitations.2 In a recent case-control selecting patients and controls from the population of study in Costa Rica, women using the drug had a New Zealand by the same criteria. Information bias significantly increased relative risk of breast cancer of was also unlikely to have affected the results: patients 2 6.4 This estimate was based on only 19 cases who and controls were interviewed in an identical way, with had used the drug, and the authors suggested that the findings could have been due to bias. The World Health Organisation is studying the risk of cancer in women using medroxyprogesterone at centres in Thailand, Kenya, and Mexico.' The most recent report from this case-control study (based on 39 cases who had used medroxyprogesterone) yielded a relative risk for all women using the drug of 1-0 (95% confidence interval 0-7 to 1 5).3 Relative risks were not shown separately for women diagnosed as having breast cancer before age 35, for women who used the drug before age 25, or for women who reported using it recently; it will be important to see whether more detailed analyses replicate our findings and, if so, which of these groups are specifically at risk. If our results are confirmed the indications for using medroxyprogesterone will need to be reassessed. The findings will also contribute to discussions about the relevance of the beagle model and about the pathogenesis of breast cancer. Objectives -To determine the symptomatic and urodynamic outcome of elective prostatectomy and to establish whether the outcome is influenced or can be predicted by preoperative urodynamic measurements.
Design-Prospective non-randomised study with follow up at a mean of 11 months after operation. Most men were assessed jointly by a urologist and a general practitioner.
Setting-Department of urology in a teaching hospital serving a large district population.
Patients-253 Men listed for elective prostatectomy because of symptoms and low urinary flow rates (<15 ml/s) and excluding those already on a waiting list or with acute urinary retention, clinically apparent prostatic cancer, and neurological or cerebrovascular disease; 217 (86%) were followed up.
Intervention -Elective prostatectomy. Main outcome measure-Classification on the basis of relief of symptoms assessed by patients and urologist and general practitioner and of symptom scores obtained by questionnaire.
Results-Of the 217 men followed up, 171 (79%) had a satisfactory subjective review and 155 (72%) had a satisfactory review and also low symptom scores. An unsatisfactory outcome was associated with preoperative symptoms of urge incontinence, small prostatic size and resected weight, low voiding pressures, and low urethral resistance. Preoperative maximum urinary flow rates did not predict outcome. Men with poor outcome could be classified into two groups: those with irritative symptoms who were more likely before operation to have had urge incontinence and detrusor instability and men with symptoms of poor urinary flow who were more likely before operation to have had a small prostate, low voiding pressures, and low urethral resistance. In patients in the second group flow rates or voiding pressures improved little after operation. Men with stable detrusors and either low urethral resistance or low voiding pressures were less likely to do well after prostatectomy, but despite these associations preoperative urodynamic measurements were unable to predict outcome accurately.
Conclusions-Prostatectomy was satisfactory in relieving symptoms and improving urodynamic measurements in most men, but even in those with classic symptoms and low urinary flow rates a substantial minority experienced little improvement afterwards and urodynamic measurements did not accurately predict outcome in individual patients.
Introduction
Men in their 40s contemplating the one in 10 chance of future prostatectomy"2will be reassured that the operation is safe' but may be disquieted by recent reports, which found that a fifth of men required a second transurethral operation within eight years,4 that many experienced little improvement in quality of life assessment,' and that persistent urinary problems were commonplace.6
In about a fifth of men prostatectomy is performed for acute or chronic retention of urine," but in the remainder it is carried out for symptoms of bladder outflow obstruction that are difficult to assess. Moreover, similar symptoms may be produced by an un-
